Luna Stelio P L, Basílio Ana C, Steagall Paulo V M, Machado Luciana P, Moutinho Flávia Q, Takahira Regina K, Brandão Cláudia V S
Department of Veterinary Surgery and Anesthesiology, School of Veterinary Medicine and Animal Science, São Paulo State University, Botucatu-SP, 18618-000, Brazil.
Am J Vet Res. 2007 Mar;68(3):258-64. doi: 10.2460/ajvr.68.3.258.
To evaluate adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.
36 adult dogs.
Values for CBC, urinalysis, serum biochemical urinalyses, and occult blood in feces were investigated before and 7, 30, 60, and 90 days after daily oral administration (n = 6 dogs/group) of lactose (1 mg/kg, control treatment), etodolac (15 mg/kg), meloxicam (0.1 mg/kg), carprofen (4 mg/kg), and ketoprofen (2 mg/kg for 4 days, followed by 1 mg/kg daily thereafter) or flunixin (1 mg/kg for 3 days, with 4-day intervals). Gastroscopy was performed before and after the end of treatment.
For serum gamma-glutamyltransferase activity, values were significantly increased at day 30 in dogs treated with lactose, etodolac, and meloxicam within groups. Bleeding time was significantly increased in dogs treated with carprofen at 30 and 90 days, compared with baseline. At 7 days, bleeding time was significantly longer in dogs treated with meloxicam, ketoprofen, and flunixin, compared with control dogs. Clotting time increased significantly in all groups except those treated with etodolac. At day 90, clotting time was significantly shorter in flunixin-treated dogs, compared with lactose-treated dogs. Gastric lesions were detected in all dogs treated with etodolac, ketoprofen, and flunixin, and 1 of 6 treated with carprofen.
Carprofen induced the lowest frequency of gastrointestinal adverse effects, followed by meloxicam. Monitoring for adverse effects should be considered when nonsteroidal anti-inflammatory drugs are used to treat dogs with chronic pain.
评估长期口服卡洛芬、依托度酸、氟尼辛葡甲胺、酮洛芬和美洛昔康对犬的不良反应。
36只成年犬。
在每日口服乳糖（1毫克/千克，对照处理）、依托度酸（15毫克/千克）、美洛昔康（0.1毫克/千克）、卡洛芬（4毫克/千克）、酮洛芬（前4天2毫克/千克，之后每日1毫克/千克）或氟尼辛（1毫克/千克，连用3天，间隔4天）之前以及用药后7、30、60和90天，对犬进行全血细胞计数、尿液分析、血清生化尿液分析以及粪便潜血检测（每组6只犬）。在治疗开始前和结束后进行胃镜检查。
对于血清γ-谷氨酰转移酶活性，在组内接受乳糖、依托度酸和美洛昔康治疗的犬中，第30天时数值显著升高。与基线相比，接受卡洛芬治疗的犬在第30天和第90天时出血时间显著延长。在第7天时，与对照犬相比，接受美洛昔康、酮洛芬和氟尼辛治疗的犬出血时间显著更长。除接受依托度酸治疗的组外，所有组的凝血时间均显著增加。在第90天时，与接受乳糖治疗的犬相比，接受氟尼辛治疗的犬凝血时间显著缩短。在所有接受依托度酸、酮洛芬和氟尼辛治疗的犬以及接受卡洛芬治疗的6只犬中的1只中检测到胃部病变。
卡洛芬引起的胃肠道不良反应发生率最低，其次是美洛昔康。当使用非甾体抗炎药治疗患有慢性疼痛的犬时，应考虑监测不良反应。
